Brock Debenham

Dr. Brock Debenham

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
NVNafeesa Vawda
Nafeesa Vawda
RBRobyn N. Banerjee
Robyn N. Banerjee
BDBrock Debenham
Brock Debenham

18 October 2013 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
AFAlysa Fairchild
Alysa Fairchild
BDBrock Debenham
Brock Debenham
BDB Danielson
B Danielson
FHF Huang
F Huang
SGS Ghosh
S Ghosh

1 October 2013 in The Lancet Oncology
Verified
Journal Article
Closed access
BDBrock Debenham
Brock Debenham
KHKenneth S Hu
Kenneth S Hu
LHLouis B Harrison
Louis B Harrison

5 September 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
SNSara Nejatinamini
Sara Nejatinamini
BDBrock Debenham
Brock Debenham
RCRobin Clugston
Robin Clugston
AMAsifa Mawani
Asifa Mawani
MPMatthew Parliament
Matthew Parliament
VMVera C Mazurak
Vera C Mazurak
Mucositis and muscle wasting are two common toxicity effects of cancer treatment in head and neck cancer (HNC). There is limited data evaluating cancer treatment toxicities in relation to vitamin status. This study aimed to assess changes in vitamin status during HNC treatment in relation to body composition, inflammation and mucositis. In this prospective cohort study, dietary intakes (3-day food record), plasma levels of vitamins and C-reactive protein (CRP) were assessed at baseline (at diagnosis) and post-treatment (after 6–8 weeks of radiation therapy with or without chemotherapy). Computed tomography images were used to quantify body composition. Mucositis information was collected from health records of patients. Twenty-eight HNC patients (age 60 ± 10 years) completed both study time points. Patients who developed mucositis had significantly lower dietary intake of vitamins and plasma 25-hydroxy vitamin D (25-OHD) and all-trans retinol levels (p < 0.02). Patients lost a considerable amount of muscle mass (3.4 kg) and fat mass (3.6 kg) over the course of treatment. There was a trend toward greater muscle loss in patients with 25-OHD < 50 nmol/L compared to patients with 25-OHD ≥ 50 nmol/L (p = 0.07). A significant negative correlation was found between plasma all-trans retinol and CRP level at the end of treatment (p = 0.03). Poor vitamin status could be a contributing factor in developing treatment-induced toxicities.

1 March 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
BDBrock Debenham
Brock Debenham
RBRobyn Banerjee
Robyn Banerjee
AFAlysa Fairchild
Alysa Fairchild
GDGeorge Dundas
George Dundas
TTTheresa Trotter
Theresa Trotter
DYDon Yee
Don Yee

17 November 2017 in Head & Neck
Verified
Journal Article
Closed access
PDF file
LLLeah A. Lechelt
Leah A. Lechelt
JRJana Rieger
Jana Rieger
KCKatherine Cowan
Katherine Cowan
BDBrock Debenham
Brock Debenham
BKBernie Krewski
Bernie Krewski
OCon behalf of the Alberta Head and Neck Cancer Priority Setting Partnership Steering Committee
on behalf of the Alberta Head and Neck Cancer Priority Setting Partnership Steering Committee